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The International Pachyonychia Conge-
nita Consortium (IPCC) was founded in
2004 in Park City, Utah, USA. The IPCC
is a group of scientists and physicians
who have agreed to work together to
develop treatments and a cure for
pachyonychia congenita, a rare kerati-
nizing disorder (PC, OMIM #16700 and
#167210). From February 14th to 17th,
2013, the group convened in Park City
for their 10th annual meeting. The IPCC
holds yearly meetings devoted to the
most pressing issues in developing treat-
ments for PC and strives to reach con-
sensus on the best way to move forward.
The 2013 meeting focused on how to
best move forward with clinical trials
and on learning from work in other
scientific areas, with an emphasis on
understanding mechanisms of pain and
hyperkeratosis. Considerable time was
spent on discussing the best way to
move forward with the development of
new treatments and how to obtain or
develop tools that can measure treat-
ment outcomes in PC.
This review will summarize the meet-
ing’s sessions and discuss the goals set
by the IPCC for the next few years. A list
of presenters and the titles of their talks
is appended at the end of this paper.
Preclinical sessions
Frances Smith discussed the genetics
of pachyonychia congenita. Mutations
in one of at least four keratin genes are
known to cause PC: KRT6A, KRT6B,
KRT16, and KRT17. Mutations in KRT6C
are associated with focal painful palmo-
plantar keratoderma (PPK) and little nail
involvement. The IPCRR has collected
clinical and molecular data from more
than 640 PC patients in more than 286
families worldwide. More than 86 dis-
tinct causative mutations have been
identified. This large data set is yielding
important insights that assist clinical
decision making, such as genotype-
phenotype correlations (described also
in (Fu et al. 2011)). In addition, the
differential diagnosis has become much
more defined (McLean et al. 2011;
Wilson et al. 2013), helping physicians
to better diagnose their patients.
Despite such advances, the pathogen-
esis of PPK in PC is still uncertain. Pierre
Coulombe discussed how his group
recently reported that Krt16 / mice
will consistently develop oral lesions
and a PPK-like hyperkeratosis on their
front paws (Lessard and Coulombe,
2012). These findings call into question
the commonly held view that PC-related
PPK results from dominantly acting
mutated keratins. Rather, Krt16 may
contribute to the proper formation of
the epidermal barrier. To test this hypo-
thesis, Krt16-deficient mice were
challenged with various mechanical
and chemical stimuli to the affected
paws. Skin barrier challenge was asso-
ciated with a transcriptional overacti-
vation of innate cellular danger signals
known as alarmins or damage-associated
molecular patterns (DAMPs, (Chan et al.
2012)), along with several known regu-
lators of the skin barrier. Alarmins are
potent mediators of inflammation and
as such have a fundamental role in the
pathogenesis of a wide range of immune
and inflammatory disorders (Chan et al.
2012). Remarkably, a similar gene
expression signature, including danger
signals, is found in biopsies of PPK
lesions obtained from involved PC
patient biopsies (collaboration with
TransDerm Inc, Santa Cruz, CA).
The signature keratoderma compo-
nent of PC, therefore, might partly reflect
an inflammatory response to abnormal
skin barrier function and stress, which
has potential implications for treatment.
To develop new treatments, animal
models such as the Krt16 / mouse
(and relevant Krt16 mutant allele
knockin mice) are needed. Delivery of
therapeutic siRNA is a key goal and is
still a major hurdle to overcome. The
McLean group has developed two
mouse models to study the efficacy of
siRNA delivery to the epidermis, one
that reports filaggrin expression and one
that shows KRT9. These models provide
a reporter for gene silencing and will
thus be helpful in developing siRNA
delivery. In addition, Krt9 knockout
mice were generated. These develop a
PPK that resembles the human condition
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associated with KRT9 mutations
(Vo¨rner’s epidermolytic PPK) and as
such are remarkably similar to the
Krt16 / mice, further supporting
the notion that impaired skin barrier
function and deregulation of inflamma-
tory responses might be important deter-
minants of the disease phenotype.
In a related talk, Robyn Hickerson
addressed intravital visualization of
siRNA targets. Transderm, Inc has
demonstrated the ability to detect fluor-
escently tagged K6a injected into mouse
skin by a recently developed intravital
fluorescence imaging system. To our
knowledge, this is the first PC mouse
model in which the disease molecular
phenotype can be observed in vivo, and
it will be used to evaluate and optimize
topical siRNA delivery technologies
(topical formulations and microneedles)
and commercially available delivery
technologies in preparation for clinical
trials. As a first step toward this goal,
Hickerson and colleagues have shown
specific inhibition of a targeted reporter
protein relative to a control in this
model by co-injection of siRNA with
the relevant expression plasmids.
About 95% of PC patients have plan-
tar pain, which can be so disabling as
to necessitate the use of a wheelchair.
Understanding what causes the severe
pain is a pertinent goal for the IPCC.
Michael Caterina discussed how it is
emerging that keratinocytes express
much of the machinery needed to trans-
duce pain and mechanical stimuli. In
particular, they have TRPV (transient
receptor potential vanilloid) channels.
TRPV channels are a family of ion
channels that are activated not only by
a range of stimuli such as heat, pressure,
and osmolarity but also by specific
ligands such as capsaicin (Gunthorpe
et al., 2002). They are particularly
prominent in nociceptive afferent nerve
endings. In humans, there are six TRPV
family members.
It has been previously published that
TRPV3 channels in keratinocytes mod-
ulate sensitivity to pain (Huang et al.,
2008) and, as was discussed by Gil
Yosipovitch, itch as well (Yamamoto-
Kasai et al. 2012). Thus, keratinocytes
seem to be integral to cutaneous
nociception, which has profound impli-
cations for understanding and treating
PC pain, particularly because vanilloid
channel blockers are actively being
developed. Involvement of nociceptive
systems in PC is further supported by
findings from a systems approach,
where array-based RNA profiles of PC
skin versus healthy skin were obtained
in five patients and controls. Yu-An Cao
from Transderm reported how these
profiles implicate genes involved in
nociception, such as two tissue kalli-
kreins. In addition, genes involved in
neurite outgrowth and neuropathy were
also found to be differentially regulated
in PC versus normal skin.
It is of interest to note that activating
mutations in TRPV3 can cause Olmsted
syndrome (Lin et al., 2012), which is
characterized by very pronounced muti-
lating PPK. It is tempting to speculate
that TRPV3 channels connect nocicep-
tion with skin barrier function—if a
damaging stimulus is detected, it makes
sense for the skin to try and strengthen
its barrier function.
Thus, it is emerging that unexpected
novel biology could be underlying the
PC phenotype, with accumulating evi-
dence for a nociceptive role for the
keratinocyte, which is proving to be an
even more flexible cell than was pre-
viously thought. It makes sense to use
systems approaches in order to under-
stand this complexity. Robert Rice dis-
cussed proteome profiling as a tool to
understand disease processes and diag-
nose them. This technology is at a
relatively early stage, but holds great
promise for assembling a complete
overview of PC pathogenesis, in addi-
tion to providing a tool that could help
distinguish PC from similar disorders.
Clinical sessions
The clinical sessions were dedicated to
learning from work on other disorders
with abnormal keratinization and nail
dysplasia and from experiences with the
study of rare diseases. In addition, con-
siderable attention was paid to the drug
development process and to acquiring
tools for monitoring drug responses.
The latter are absolutely essential to
properly evaluate the effect of therapeu-
tic interventions.
Sharon Savage spoke on dyskeratosis
congenita (DC), a rare disorder caused
by failure to maintain telomeres.
Symptoms include bone marrow failure,
leukemia, and epithelial malignancies.
The diagnosis is often based on patients
presenting with a classical triad of poi-
kiloderma, severe nail dysplasia, and
oral leukoplakia. Sharon Savage is
involved in a longitudinal cohort study
of people with DC and their relatives,
which is yielding very insightful data on
the mutation spectrum associated with
the disorder, genotype-phenotype corre-
lations, and its natural history. The
International Pachyonychia Congenita
Research Registry (IPCRR) likewise is a
treasure trove of information, and the
example of DC serves to underscore
how important consistent and longitu-
dinal follow-up is for improving patient
care.
Care may also be improved by
increasing our understanding of PC’s
pathogenesis. Other rare disorders asso-
ciated with PPK and nail dysplasia
can provide fresh insights. Maurice
van Steensel discussed cutaneous gap
junction disorders. Mutations in skin-
expressed gap junction genes (connex-
ins) cause a plethora of skin phenotypes,
all characterized by varying degrees of
hyperkeratosis (de Zwart-Storm et al.
2009). Although gap junctions are
known to be involved in intercellular
communication, the relation between
connexin gene mutations and their
associated diseases has long remained
elusive. In recent years, however, it has
become increasingly clear that inflam-
mation and endoplasmic reticulum
stress are key mechanisms in gap junc-
tion disorders. A very recent finding from
the van Steensel lab connects these
mechanisms by showing that specific
mutations in the connexin gene GJB3
cause massive endoplasmic reticulum
stress leading to cellular necrosis; the
latter will cause inflammation. As such,
gap junction disorders provide addi-
tional evidence that inflammatory
signaling has a very important role in
hyperkeratosis and should be thoroughly
explored for therapeutic targets.
As a further example, we can learn
about thickening of nails by looking at
disorders that lead to thinning of the
nails. Eli Sprecher shared his data on a
novel autosomal recessive osteocuta-
neous disorder featuring short and thick
long bones, hypoplastic nails, facial
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dysmorphism, and sparse hair (Sarig
et al. 2012). This new disorder was
termed SOFT syndrome (short stature-
onychodysplasia-facial dysmorphism-
hypotrichosis syndrome). Homozygosity
mapping and exome sequencing in two
families subsequently revealed a disease-
causing mutation in the POC1A gene
coding for a protein that has a role
in centrosome function. Indeed, patient
cells showed abnormal centrosomes
and attendant abnormalities in cell cycle
progression. Of interest, centrosomes are
emerging as major determinants of Golgi
complex stability (Sutterlin and Colanzi,
2010), and patient cells accordingly
showed abnormal architecture with com-
promised function of the Golgi appa-
ratus. SOFT syndrome shows that the
cell’s secretory system is another place
to look for better understanding of nail
formation.
Moving forward with treatment
Although basic research is progressing,
most of its findings have yet to be
translated into clinical practice. As the
IPCC mission is to find treatments and,
ultimately, a cure for PC, translational
research is actively pursued. A few years
ago, it was discovered that mammalian
target of rapamycin (mTOR) activity is
partly regulated by keratin 17 (Kim
et al., 2006). mTOR is a protein com-
plex that sits at the crossroads of energy
sensing and growth regulation, having a
key role in regulating protein synthesis
in response to external cues such as
growth factors (Yecies and Manning,
2011). Numerous hyperproliferative
conditions are characterized by increa-
sed mTOR activity and are responsive
to its inhibition with drugs such as
rapamycin (Sudarsanam and Johnson,
2010). mTOR regulation by keratins
suggests that modulation of mTOR
activity could be a viable therapeutic
strategy in some keratinizing disorders.
Moreover, Hickerson et al., noted that
the presence of TOP motifs in the
50 UTR of KRT6a and KRT6b sugges-
ted that the expression of these genes
might be reduced by rapamycin treat-
ment (Hickerson et al. 2009). Indeed,
systemic rapamycin improved symp-
toms in three PC patients. Unfortu-
nately, all patients suffered from
well-known systemic side effects.
These encouraging results suggest that
topical application of rapamycin might
offer therapeutic benefit. Joyce Teng
presented a study in which a 1% rapa-
mycin ointment caused regression of
skin lesions in tuberous sclerosis com-
plex, a disorder characterized by an
uncontrolled mTOR activity (Haemel
et al. 2010). There was no absorption,
and systemic toxicity was absent.
The meeting identified that the IPCC
needs to be better equipped to perform
clinical trials of promising treatments
such as topical rapamycin. Assessment
tools that can reproducibly gauge treat-
ment responses need to be developed.
Quality of life (QoL) is a vital outcome
parameter, but no specific questionnaire
exists for individuals suffering from
pachyonychia congenita (PC). Mariam
Abbas reported on her work together
with the IPCC to (1) develop a ques-
tionnaire specific for PC and (2) assess
the validity and reliability of a new
quality-of-life instrument for patients
with PC (Pachyonychia Congenita Qual-
ity of Life -PCQoL). Her results to date
suggest that both tools are reliable and
fit for use in clinical trials.
Next to QoL, callus thickness is the
other crucial outcome for any clinical
trial in PC. Skin biopsies are not a
preferred method for measuring callus
thickness. Local anesthesia is painful
and only small areas can be sampled.
Tools are needed that can reliably and
reproducibly measure callus thickness
over larger surface areas of the feet. Ian
Goldberg reported results from a study
on 16 patients with PPK (seven of whom
had PC), who underwent high-resolu-
tion multifrequency ultrasound exami-
nation of the plantar skin. Ultrasound
scanning techniques performed over the
calluses and at the proximal and distal
plantar sites on both feet in PC patients
demonstrated hyperechoic dots and
lines within the epidermis compatible
with hyperkeratinization, engorged var-
icose veins in the dermis, and an anec-
hoic layer interposed between the
epidermis and the dermis, correspond-
ing to blister fluid underneath the cal-
luses. Patients with other types of PPK
did not show any blisters. This finding
may help in the diagnosis of PC. The
results from this study suggest that high-
resolution ultrasound might be used to
monitor callus thickness. As the techni-
que is relatively easy to learn and is
non-invasive, it could be a very useful
tool to track the treatment outcome.
Ajit Simh explained to the attendees
how to deal with the complex regula-
tory issues that surround the develop-
ment of novel drugs or the repurposing
of existing ones. The process is com-
plex, but the story of Excaliard pharma-
ceuticals (now acquired by Pfizer) as
recounted by Nicholas Dean showed
that it can be navigated in a relatively
limited time. This precedent offers hope
for people with PC—once an effective
treatment becomes available, it needs to
reach patients as quickly as possible.
Finally, Roger Kaspar and Tycho
Speaker (TransDerm) discussed current
progress on two therapeutic programs,
topical rapamycin and self-delivery
siRNA (sdTD101). They noted that man-
ufacturing of dissolvable microneedles
(to deliver siRNAs while minimizing
pain) had been accomplished under
GMP conditions, and that a GLP mouse
study had been completed (with no
signs of toxicity). Both of these programs
are on track for phase 1b clinical trials,
likely beginning this year. Pre-IND
meetings have been scheduled with
the FDA in the coming months to initi-
ate this process. Other potential clinical
studies were also discussed, but there
was general agreement among attendees
that these two programs should be the
priority at the present time.
Conclusion
Impressive progress has been made in
our understanding of PC genetics, assis-
ted greatly by the IPCCR. The patho-
physiology of PC remains elusive, but
there are promising recent advances.
Novel animal models and high-through-
put technology can be expected to
provide important insights within the
next few years. Meanwhile, the devel-
opment of topical rapamycin and siRNA
continues and will enter into clinical
trials later this year. The IPCC recog-
nizes that clinical outcome measures
need to be developed and is devoting
considerable resources to this issue.
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List of presenters, with titles of their talks
(in alphabetical order)
Mariam Abbas, "PCQoL: a quality of
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high resolution multifrequency ultra-
sound of the plantar skin"
Robyn Hickerson, "Intravital visuali-
zation of mutant keratin 6a inhibition by
siRNA in mouse skin"
Roger Kaspar, "Upcoming sd101 and
topical rapamycin clinical trials"
W.H. Irwin McLean, "Mouse models
of keratoderma and for optimizing
siRNA delivery"
Robert H. Rice, "Corneocyte proteo-
mic profiles: possible application to skin
disease?"
Frances J.D. Smith, "Genetics of
pachyonychia congenita"
Edel O’Toole, "Pachyonychia conge-
nita: what we know: 2013"
Sharon A. Savage, "Dyskeratosis con-
genita: a rare but highly informative
telomere biology disorder"
Ajit Simh, "Regulatory requirements
for human clinical trials"
Tycho J. Speaker, "Upcoming sd101
and topical rapamycin clinical trials"
Eli Sprecher, "A soft story"
Maurice A.M. van Steensel, "Con-
nexin-mediated skin disease"
Joyce M. Teng, "Topical rapamycin
for genetic skin disease and transepider-
mal delivery"
Gil Yosipovitch, "Itchy skin: scratch-
ing for an explanation"
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